Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021

医薬品有効成分/APIの世界市場予測(~2021):種類別(新薬、ジェネリック)、メーカー別、合成別、製品別、薬品別、治療別

◆タイトル:Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021
◆商品コード:MAM-PH-1262
◆調査・発行会社:MarketsandMarkets
◆発行日:2017年1月10日
◆ページ数:315
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥610,200見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥718,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥880,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、医薬品有効成分/APIの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、種類別分析、メーカー別分析、合成別分析、製品別分析、医薬品有効成分/APIの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global active pharmaceutical ingredients market is expected to reach USD 213.97 Billion by 2021 from USD 157.95 Billion in 2016, growing at a CAGR of 6.3% from 2016 to 2021. The market is segmented on the basis type, type of manufacturer, type of synthesis, type of drug, therapeutic application, and region.
Market growth is driven by the increasing incidence of chronic diseases, rising prevalence of cancer, technological advancements in API manufacturing, growing importance of generics, rapidly increasing geriatric population, increase in abbreviated new drug applications (ANDA) and increasing uptake of biopharmaceuticals. Furthermore, emerging biosimilars market, increasing scope for HPAPIs, emerging markets and emerging technologies have opened an array of opportunities for the growth of the market. However, factors such as stringent regulatory requirements and unfavorable drug price control policies across various countries may restrain the growth of this market.

Based on type, the APIs market is segmented into innovative and generic APIs. The innovative APIs segment is expected to account for the largest share in 2016. The large share of this segment can be attributed to the increasing number of FDA approvals for new molecular entities, higher price commanded by innovative APIs as compared to their generic equivalents, and growing focus of innovator APIs companies on R&D for the development of novel innovative APIs products to cater to the previously unmet medical needs of the market

On the basis of type of manufacturer, the APIs market is segmented into captive and merchant manufacturers. The captive manufacturers segment is estimated to account for the largest share in 2016. The large share of this segment can be can be attributed to the growing preference of companies to maintain in-house manufacturing of innovative APIs for their economic benefits.

On the basis of type of synthesis the, the APIs market is categorized into synthetic and biotech APIs. The synthetic APIs segment is estimated to command the largest in 2016. The emergence of new molecules in the market, increasing number of new product approvals, and technological advancements in the method of synthesis are major factors contributing to the growth of the synthetic APIs segment. However, the biotech APIs segment is expected to grow at the highest CAGR in the forecast period.

The APIs market, on the basis of type of drug, is segmented into prescription drugs and over-the-counter (OTC) drugs. In 2016, the prescription drugs segment is estimated to account for the largest share of the APIs market. The large share of this segment can primarily be attributed to the increasing demand for these drugs owing to the growing incidence of diseases such as cancer, cardiovascular disease, and respiratory disorders.

The APIs market, on the basis of therapeutic applications, is segmented into oncology, cardiovascular diseases, diabetes, endocrinology, central nervous system (CNS) and neurological disorders, and other therapeutic applications. The oncology segment is estimated to account for the largest of the global active pharmaceutical ingredients market in 2016. The large share of this segment can be attributed to the increasing incidence and prevalence of cancer globally, growing focus of pharmaceutical companies for the development of novel products for cancer treatment, and growing investments in the research activities for the development of novel therapies like targeted therapies which utilize anti-body drug conjugates for the treatment of cancer.

The global active pharmaceutical ingredients market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to lead the global market in the forecast period. Over the next five years, Asia Is expected to register highest growth rate.

Some of the prominent players in the market include Pfizer Inc. (U.S.), Novartis International AG (Switzerland), Merck & Co. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Mylan, Inc. (U.S.), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (U.S.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), and GlaxoSmithKline plc (U.K.).

【レポートの目次】

1 Introduction (Page No. – 28)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Market Stakeholders

2 Research Methodology (Page No. – 32)
2.1 Market Size Estimation
2.2 Market Breakdown and Data Triangulation
2.3 Key Data From Secondary Sources
2.4 Key Data From Primary Sources
2.5 Key Industry Insights
2.6 Assumptions for the Study

3 Executive Summary (Page No. – 41)

4 Premium Insights (Page No. – 47)
4.1 Active Pharmaceutical Ingredients Market Overview
4.2 Active Pharmaceutical Ingredients Market, By Type of Manufacturer
4.3 Active Pharmaceutical Ingredients Market, By Therapeutic Area
4.4 Biotech Active Pharmaceutical Ingredients Market, By Product
4.5 Active Pharmaceutical Ingredients Market, By Type of Drug
4.6 Active Pharmaceutical Ingredients Market: Geographic Snapshot

5 Market Overview (Page No. – 52)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increasing Incidence of Chronic Diseases
5.2.1.2 Rising Prevalence of Cancer
5.2.1.3 Technological Advancements in Api Manufacturing
5.2.1.4 Growing Importance of Generics
5.2.1.5 Rapidly Increasing Geriatric Population
5.2.1.6 Increase in Abbreviated New Drug Applications (ANDA)
5.2.1.7 Increasing Uptake of Biopharmaceuticals
5.2.2 Restraints
5.2.2.1 Stringent Regulatory Requirements
5.2.2.2 Unfavorable Drug Price Control Policies Across Various Countries
5.2.3 Opportunities
5.2.3.1 Emerging Biosimilars Market
5.2.3.2 Increasing Scope for High-Potency Active Pharmaceutical Ingredients
5.2.3.3 Emerging Markets
5.2.3.4 Emerging Technologies
5.2.4 Challenges
5.2.4.1 Product Differentiation
5.2.4.2 High Manufacturing Costs

6 Active Pharmaceutical Ingredients Market, By Type (Page No. – 64)
6.1 Introduction
6.2 Innovative Active Pharmaceutical Ingredients
6.3 Generic Active Pharmaceutical Ingredients

7 Active Pharmaceutical Ingredients Market, By Type of Manufacturer (Page No. – 73)
7.1 Introduction
7.2 Captive Manufacturers
7.3 Merchant Api Manufacturers
7.3.1 Merchant Manufacturers Market, By Type
7.3.1.1 Innovative Merchant Api Manufacturers
7.3.1.2 Generic Merchant Api Manufacturers
7.3.2 Merchant Api Manufacturers Market, By Mode of Synthesis
7.3.2.1 Synthetic APIS
7.3.2.2 Biotech APIS

8 Active Pharmaceutical Ingredients Market, By Type of Synthesis (Page No. – 92)
8.1 Introduction
8.2 Synthetic Active Pharmaceutical Ingredients
8.2.1 Synthetic Active Pharmaceutical Ingredients Market, By Type
8.2.1.1 Innovative Synthetic APIS
8.2.1.2 Generic Synthetic APIS
8.3 Biotech Active Pharmaceutical Ingredients
8.3.1 Biotech Active Pharmaceutical Ingredients Market, By Type
8.3.1.1 Innovative Biotech APIS
8.3.1.2 Biosimilars
8.3.2 Biotech Active Pharmaceutical Ingredients Market, By Product
8.3.2.1 Monoclonal Antibodies
8.3.2.2 Vaccines
8.3.2.3 Hormones and Growth Factors
8.3.2.4 Cytokines
8.3.2.5 Fusion Proteins
8.3.2.6 Therapeutic Enzymes
8.3.2.7 Blood Factors
8.3.3 Biotech Active Pharmaceutical Ingredients Market, By Expression System
8.3.3.1 Mammalian Expression Systems
8.3.3.2 Microbial Expression Systems
8.3.3.3 Yeast Expression Systems
8.3.3.4 Plant Expression Systems
8.3.3.5 Insect Expression Systems

9 Active Pharmaceutical Ingredients Market, By Type of Drug (Page No. – 138)
9.1 Introduction
9.2 Prescription Drugs
9.3 Over-The-Counter Drugs
9.4 Active Pharmaceutical Ingredients Market, By Potency
9.4.1 Low to Moderate Potency Active Pharmaceutical Ingredients
9.4.2 Potent to Highly Potent Active Pharmaceutical Ingredients

10 Active Pharmaceutical Ingredients Market, By Therapeutic Application (Page No. – 149)
10.1 Introduction
10.2 Oncology
10.3 Cardiovascular Disease
10.4 Diabetes
10.5 Central Nervous System and Neurological Disorders
10.6 Endocrinology
10.7 Other Therapeutic Applications

11 Active Pharmaceutical Ingredients Market, By Region (Page No. – 167)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 France
11.3.3 U.K.
11.3.4 Italy
11.3.5 Spain
11.3.6 Rest of Europe (RoE)
11.4 Asia
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 South Korea
11.4.5 Rest of Asia (RoA)
11.5 Rest of the World (RoW)

12 Competitive Landscape (Page No. – 263)
12.1 Overview
12.2 Market Player Ranking
12.3 Competitive Situation and Trends
12.3.1 Agreements, Collaborations, Partnerships, Joint Ventures, and Alliances
12.3.2 Regulatory Approvals
12.3.3 Mergers and Acquisitions
12.3.4 Expansions
12.3.5 Investments

13 Company Profiles (Page No. – 271)
(Company at A Glance, Business Overview, Products Offered, Key Strategy, Recent Developments, SWOT Analysis & MnM View)*
13.1 Introduction
13.2 Pfizer, Inc.
13.3 Novartis International AG
13.4 Sanofi
13.5 Boehringer Ingelheim
13.6 Bristol-Myers Squibb
13.7 Teva Pharmaceutical Industries Ltd.
13.8 ELI Lilly and Company
13.9 Glaxosmithkline PLC
13.10 Merck & Co., Inc.
13.11 Abbvie Inc.

*Details on Company at A Glance, Recent Financials, Products Offered, Strategies & Insights, & Recent Developments Might Not Be Captured in Case of Unlisted Companies.

14 Appendix (Page No. – 297)
14.1 Insights From Industry Experts
14.2 Discussion Guide
14.3 Other Developments
14.4 Introducing RT: Real-Time Market Intelligence
14.5 Knowledge Store: Marketsandmarkets’ Subscription Portal
14.6 Available Customizations
14.7 Related Reports
14.8 Author Details

List of Tables (369 Tables)

Table 1 Indicative List of Generic Drugs That Gained Approval in 2016
Table 2 Statistics on Aging Population
Table 3 Indicative List of Biologics That Gained U.S. Regulatory Approval in 2015–2016
Table 4 Increasing Incidence of Chronic Diseases: A Major Market Driver
Table 5 Stringent Regulatory Requirements: A Major Restraint for Market Growth
Table 6 Emerging Markets Offer Significant Growth Opportunities
Table 7 Stringent Regulatory Guidelines: A Major Challenge for Market Growth
Table 8 Market Size, By Type, 2014-2021 (USD Billion)
Table 9 Indicative List of New Molecular Entities That Gained U.S. FDA Approval in 2016
Table 10 Significant Patent Expiries, 2015
Table 11 Innovative Active Pharmaceutical Ingredients Market Size, By Region, 2014-2021 (USD Billion)
Table 12 North America: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 13 Europe: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 14 Asia: Innovative Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 15 Generic Active Pharmaceutical Ingredients Market, By Region, 2014-2021 (USD Billion)
Table 16 North America: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 17 Europe: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 18 Asia: Generic Active Pharmaceutical Ingredients Market Size, By Country, 2014-2021 (USD Billion)
Table 19 Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 20 Captive Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 21 North America: Captive Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 22 Europe: Captive Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 23 Asia: Captive Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 24 List of Significant Mergers and Acquisitions in the Cmo/Cdmo Industry
Table 25 List of Significant Cmo/Cdmo Facility Expansions
Table 26 Merchant Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 27 North America: Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 28 Europe: Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 29 Asia: Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 30 Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 31 Innovative Merchant Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 32 North America: Innovative Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 33 Europe: Innovative Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 34 Asia: Innovative Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 35 Generic Merchant Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 36 North America: Generic Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 37 Europe: Generic Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 38 Asia: Generic Merchant Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 39 Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 40 Merchant Synthetic Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 41 North America: Merchant Synthetic Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 42 Europe: Merchant Synthetic Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 43 Asia: Merchant Synthetic Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 44 Merchant Biotech Api Manufacturers Market Size, By Region, 2014–2021 (USD Billion)
Table 45 North America: Merchant Biotech Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 46 Europe: Merchant Biotech Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 47 Asia: Merchant Biotech Api Manufacturers Market Size, By Country, 2014–2021 (USD Billion)
Table 48 Market Size, By Type of Synthesis, 2014–2021 (USD Billion)
Table 49 Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
Table 50 North America: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 51 Europe: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 52 Asia: Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 53 Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 54 Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
Table 55 North America: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 56 Europe: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 57 Asia: Innovative Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 58 Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
Table 59 North America: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 60 Europe: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 61 Asia: Generic Synthetic Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 62 Top Selling Biologics (2015)
Table 63 Biotech Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
Table 64 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 65 Europe: Biotech Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 66 Asia: Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 67 Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 68 Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Region, 2014–2021 (USD Billion)
Table 69 North America: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 70 Europe: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 71 Asia: Innovative Biotech Active Pharmaceutical Ingredients Market Size, By Country, 2014–2021 (USD Billion)
Table 72 Biosimilars Market Size, By Region, 2014–2021 (USD Billion)
Table 73 North America: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
Table 74 Europe: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
Table 75 Asia: Biosimilars Market Size, By Country, 2014–2021 (USD Billion)
Table 76 Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
Table 77 Indicative List of Monoclonal Antibodies That Received FDA Approval in 2016
Table 78 Monoclonal Antibodies Market Size, By Region, 2014–2021 (USD Billion)
Table 79 North America: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
Table 80 Europe: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
Table 81 Asia: Monoclonal Antibodies Market Size, By Country, 2014–2021 (USD Billion)
Table 82 Vaccines Market Size, By Region, 2014–2021 (USD Million)
Table 83 North America: Vaccines Market Size, By Country, 2014–2021 (USD Million)
Table 84 Europe: Vaccines Market Size, By Country, 2014–2021 (USD Million)
Table 85 Asia: Vaccines Market Size, By Country, 2014–2021 (USD Million)
Table 86 Hormones and Growth Factors Market Size, By Region, 2014–2021 (USD Billion)
Table 87 North America: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
Table 88 Europe: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
Table 89 Asia: Hormones and Growth Factors Market Size, By Country, 2014–2021 (USD Billion)
Table 90 Cytokines Market Size, By Region, 2014–2021 (USD Billion)
Table 91 North America: Cytokines Market Size, By Country, 2014–2021 (USD Billion)
Table 92 Europe: Cytokines Market Size, By Country, 2014–2021 (USD Million)
Table 93 Asia: Cytokines Market Size, By Country, 2014–2021 (USD Million)
Table 94 Fusion Proteins Market Size, By Region, 2014–2021 (USD Billion)
Table 95 North America: Fusion Proteins Market Size, By Country, 2014–2021 (USD Billion)
Table 96 Europe: Fusion Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 97 Asia: Fusion Proteins Market Size, By Country, 2014–2021 (USD Million)
Table 98 Therapeutic Enzymes Market Size, By Region, 2014–2021 (USD Billion)
Table 99 North America: Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
Table 100 Europe: Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
Table 101 Asia: Merchant Therapeutic Enzymes Market Size, By Country, 2014–2021 (USD Million)
Table 102 Blood Factors Market Size, By Region, 2014–2021 (USD Million)
Table 103 North America: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
Table 104 Europe: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
Table 105 Asia: Blood Factors Market Size, By Country, 2014–2021 (USD Million)
Table 106 Biotech Active Pharmaceutical Ingredients Market Size, By Expression System, 2014–2021 (USD Billion)
Table 107 Mammalian Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
Table 108 North America: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 109 Europe: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 110 Asia: Mammalian Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 111 Microbial Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
Table 112 North America: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 113 Europe: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 114 Asia: Microbial Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 115 Yeast Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
Table 116 North America: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 117 Europe: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 118 Asia: Yeast Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 119 Plant Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
Table 120 North America: Plant Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 121 Europe: Plant Expression Systems Market Size, By Country, 2014–2021 (USD Million)
Table 122 Asia: Other Expression Systems Market Size, By Country, 2014–2021 (USD Million)
Table 123 Insect Expression Systems Market Size, By Region, 2014–2021 (USD Billion)
Table 124 North America: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Billion)
Table 125 Europe: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Million)
Table 126 Asia: Insect Expression Systems Market Size, By Country, 2014–2021 (USD Million)
Table 127 Global Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 128 Global Market Size for Prescription Drugs, By Region, 2014–2021 (USD Billion)
Table 129 North America: Market Size for Prescription Drugs, By Country, 2014–2021 (USD Billion)
Table 130 Europe: Market Size for Prescription Drugs, By Country, 2014–2021 (USD Billion)
Table 131 Asia: Market Size for Prescription Drugs, Country, 2014–2021 (USD Billion)
Table 132 Prescription-To-Otc Switch List in the U.S.
Table 133 Global Market Size for Over-The-Counter Drugs, By Region, 2014–2021 (USD Billion)
Table 134 North America: Market Size for Over-The-Counter Drugs, By Country, 2014–2021 (USD Billion)
Table 135 Europe: Market Size for Over-The-Counter Drugs, By Country, 2014–2021 (USD Billion)
Table 136 Asia: Market Size for Over-The-Counter Drugs, By Country, 2014–2021 (USD Billion)
Table 137 Market Size, By Potency, 2014-2021 (USD Billion)
Table 138 Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 139 Cancer: Estimated Incidence, Mortality, and Prevalence (2012)
Table 140 Market Size for Oncology, By Region, 2014–2021 (USD Billion)
Table 141 North America: Market Size for Oncology, By Country, 2014–2021 (USD Billion)
Table 142 Europe: Market Size for Oncology, By Country, 2014–2021 (USD Billion)
Table 143 Asia: Market Size for Oncology, By Country, 2014–2021 (USD Billion)
Table 144 Market Size for Cvd, By Region, 2014–2021 (USD Billion)
Table 145 North America: Market Size for Cvd, By Country, 2014–2021 (USD Billion)
Table 146 Europe: Market Size for Cvd, By Country, 2014–2021 (USD Billion)
Table 147 Asia: Market Size for Cvd, By Country, 2014–2021 (USD Billion)
Table 148 Market Size for Diabetes, By Region, 2014–2021 (USD Billion)
Table 149 North America: Market Size for Diabetes, By Country, 2014–2021 (USD Billion)
Table 150 Europe: Market Size for Diabetes, By Country, 2014–2021 (USD Billion)
Table 151 Asia: Market Size for Diabetes, By Country, 2014–2021 (USD Billion)
Table 152 Market Size for Cns and Neurological Disorders, By Region, 2014–2021 (USD Billion)
Table 153 North America: Market Size for Cns and Neurological Disorders, By Country, 2014–2021 (USD Billion)
Table 154 Europe: Market Size for Cns and Neurological Disorders, By Country, 2014–2021 (USD Billion)
Table 155 Asia: Market Size for Cns and Neurological Disorders, By Country, 2014–2021 (USD Billion)
Table 156 Market Size for Endocrinology, By Region, 2014–2021 (USD Billion)
Table 157 North America: Market Size for Endocrinology, By Country, 2014–2021 (USD Billion)
Table 158 Europe: Market Size for Endocrinology, By Country, 2014–2021 (USD Billion)
Table 159 Asia: Market Size for Endocrinology, By Country, 2014–2021 (USD Billion)
Table 160 Market Size for Other Therapeutic Applications, By Region, 2014–2021 (USD Billion)
Table 161 North America: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Billion)
Table 162 Europe: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Billion)
Table 163 Asia: Market Size for Other Therapeutic Applications, By Country, 2014–2021 (USD Billion)
Table 164 Global Market Size, By Region, 2014–2021 (USD Billion)
Table 165 North America: Market Size, By Country, 2014–2021 (USD Billion)
Table 166 North America: Market Size, By Type, 2014–2021 (USD Billion)
Table 167 North America: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 168 North America: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 169 North America: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 170 North America: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 171 North America: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 172 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 173 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Billion)
Table 174 North America: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
Table 175 North America: Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 176 North America: Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 177 Recent FDA Approvals for NDA and ANDA
Table 178 U.S.: Market Size, By Type, 2014–2021 (USD Billion)
Table 179 U.S.: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 180 U.S.: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 181 U.S.: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 182 U.S.: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 183 U.S.: Synthetic Market Size, By Type, 2014–2021 (USD Billion)
Table 184 U.S.: Biotech Market Size, By Type, 2014–2021 (USD Billion)
Table 185 U.S.: Biotech Market Size, By Product, 2014–2021 (USD Billion)
Table 186 U.S.: Biotech Market Size, By Type of Expression System, 2014–2021 (USD Billion)
Table 187 U.S.: Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 188 U.S.: Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 189 Canada: Market Size, By Type, 2014–2021 (USD Billion)
Table 190 Canada: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 191 Canada: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 192 Canada: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 193 Canada: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 194 Canada: Synthetic Market Size, By Type, 2014–2021 (USD Billion)
Table 195 Canada: Biotech Market Size, By Type, 2014–2021 (USD Billion)
Table 196 Canada: Biotech Market Size, By Product, 2014–2021 (USD Million)
Table 197 Canada: Biotech Market Size, By Type of Expression System, 2014–2021 (USD Billion)
Table 198 Canada: Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 199 Canada: Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 200 Europe: Market Size, By Type, 2014–2021 (USD Billion)
Table 201 Europe: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 202 Europe: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 203 Europe: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 204 Europe: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 205 Europe: Synthetic Market Size, By Type, 2014–2021 (USD Billion)
Table 206 Europe: Biotech Market Size, By Type, 2014–2021 (USD Billion)
Table 207 Europe: Biotech Market Size, By Product, 2014–2021 (USD Billion)
Table 208 Europe: Biotech Market Size, By Type of Expression System, 2014–2021 (USD Billion)
Table 209 Europe: Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 210 Europe: Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 211 Germany: Market Size, By Type, 2014–2021 (USD Billion)
Table 212 Germany: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 213 Germany: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 214 Germany: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 215 Germany: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 216 Germany: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 217 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 218 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
Table 219 Germany: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)
Table 220 Germany: Market Size, By Type of Drug, 2014–2021 (USD Billion)
Table 221 Germany: Market Size, By Therapeutic Application, 2014–2021 (USD Billion)
Table 222 France: Market Size, By Type, 2014–2021 (USD Billion)
Table 223 France: Market Size, By Type of Manufacturer, 2014–2021 (USD Billion)
Table 224 France: Merchant Api Manufacturers Market Size, By Type, 2014–2021 (USD Billion)
Table 225 France: Merchant Api Manufacturers Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 226 France: Market Size, By Mode of Synthesis, 2014–2021 (USD Billion)
Table 227 France: Synthetic Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 228 France: Biotech Active Pharmaceutical Ingredients Market Size, By Type, 2014–2021 (USD Billion)
Table 229 France: Biotech Active Pharmaceutical Ingredients Market Size, By Product, 2014–2021 (USD Million)
Table 230 France: Biotech Active Pharmaceutical Ingredients Market Size, By Type of Expression System, 2014–2021 (USD Billion)

List of Figures (46 Figures)

Figure 1 Research Design
Figure 2 Market Size Estimation: Bottom-Up Approach
Figure 3 Market Size Estimation: Top-Down Approach
Figure 4 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 5 Data Triangulation Methodology
Figure 6 Active Pharmaceutical Ingredients Market Size, By Type, 2016 vs 2021
Figure 7 Active Pharmaceutical Ingredients Market Size, By Type of Manufacturer, 2016 vs 2021
Figure 8 Active Pharmaceutical Ingredients Market Size, By Type of Synthesis, 2016 vs 2021
Figure 9 Biotech Active Pharmaceuticals Ingredients Market Size, By Product: Monoclonal Antibodies to Dominate the Market in 2016
Figure 10 Active Pharmaceutical Ingredients Market Size, By Therapeutic Application, 2016 vs 2021
Figure 11 Geographic Snapshot of the Active Pharmaceutical Ingredients Market
Figure 12 Growing Importance of Generics, the Major Factor Driving the Growth of the Market
Figure 13 Captive Manufacturers Segment to Account for the Largest Market Share in 2016
Figure 14 Oncology Segment to Witness Highest Growth During the Forecast Period
Figure 15 Monoclonal Antibodies Segment to Witness Highest Growth During the Forecast Period
Figure 16 Over-The-Counter Drugs to Witness Highest Growth From 2016–2021
Figure 17 Asia to Witness Highest Growth in the Active Pharmaceutical Ingredients Market During the Forecast Period
Figure 18 Active Pharmaceutical Ingredients Market: Drivers, Restraints, Opportunities, and Challenges
Figure 19 Innovative Segment to Dominate the Market in 2016
Figure 20 Captive Manufacturers to Dominate the Market in 2016
Figure 21 North America to Dominate the Market for Captive Manufacturers in 2016
Figure 22 Synthetic Active Pharmaceutical Ingredients Segment to Dominate the Market in 2016
Figure 23 North America to Dominate Synthetic Active Pharmaceutical Ingredients Market in 2016
Figure 24 Prescription Drugs to Dominate the Active Pharmaceutical Ingredients Market, By Type of Drug, in 2016
Figure 25 Low to Moderate Segment to Dominate the Active Pharmaceutical Ingredients Market, By Potency, in 2016
Figure 26 Oncology Segment to Dominate the Active Pharmaceutical Ingredients Market, By Therapeutic Application
Figure 27 North America to Dominate the Oncology Active Pharmaceutical Ingredients Market, By Region
Figure 28 Asia to Witness Highest Growth During the Forecast Period (2016–2021)
Figure 29 North America to Hold the Largest Share of the Global Active Pharmaceutical Ingredients Market (2016)
Figure 30 European Active Pharmaceutical Ingredients Market Snapshot (2016)
Figure 31 Asia: Active Pharmaceutical Ingredients Market Snapshot (2016)
Figure 32 RoW: Active Pharmaceutical Ingredients Market Snapshot
Figure 33 Key Developments in the Active Pharmaceutical Ingredients Market, 2013–2016
Figure 34 Market Evolution Framework—Agreements, Partnerships, Collaborations, Joint Ventures, and Alliances Fueled Market Growth
Figure 35 Battle for Market Share: Agreements, Partnerships, Collaborations, Joint Ventures, and Alliances Was the Key Strategy Adopted By Market Players (2013–2016)
Figure 36 Geographic Mix of the Top 5 Players
Figure 37 Pfizer, Inc.: Company Snapshot
Figure 38 Novartis International AG: Company Snapshot
Figure 39 Sanofi: Company Snapshot
Figure 40 Boehringer Ingelheim: Company Snapshot
Figure 41 Bristol-Myers Squibb: Company Snapshot
Figure 42 Teva Pharmaceutical Industries Ltd.: Company Snapshot
Figure 43 ELI Lilly and Company: Company Snapshot
Figure 44 Glaxosmithkline PLC: Company Snapshot
Figure 45 Merck & Co., Inc.: Company Snapshot
Figure 46 Abbvie Inc.: Company Snapshot


【レポートのキーワード】

医薬品有効成分、API、医薬品有効成分種類、新薬、ジェネリック、メーカー、合成、製品、薬品、治療

★調査レポート[医薬品有効成分/APIの世界市場予測(~2021):種類別(新薬、ジェネリック)、メーカー別、合成別、製品別、薬品別、治療別] ( Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021 / MAM-PH-1262) 販売に関する免責事項
[医薬品有効成分/APIの世界市場予測(~2021):種類別(新薬、ジェネリック)、メーカー別、合成別、製品別、薬品別、治療別] ( Active Pharmaceutical Ingredients/API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone) Drug (OTC, Rx), Therapy (Diabetes, Oncology, CNS, CVD) - Global Forecast to 2021 / MAM-PH-1262) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆